《新股表现》麦迪卫康(02159.HK)暗盘高开6.7%报3.2元
根据辉立交易平台显示,明天挂牌的麦迪卫康(02159.HK)暗盘高开6.7%报3.2元,曾掉头倒跌低见2.81元获承接,最高见3.4元,现造3.25元,较上市价3元,高8.3%,成交175万股。
麦迪卫康是内地最大心脑血管疾病综合医疗营销解决方案市场提供商。是次来港上市共发售5,000万股,其中10%公开发售获近168倍超购,已启动回拨机制占比增至50%,认购一手中签率15%;股份以招股范围(3-4元)下限定价,料集资净额约8,930万元,主要用作拓展公司客户群、疾病覆盖范围及患者群;通过开发互联网医院服务补充集团服务能力,以及扩充CRO服务等。上市独家保荐人光银国际。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.